Previous 10 | Next 10 |
2024-07-12 10:27:31 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk once-weekly insulin rejected by FDA ...
2024-07-12 08:41:47 ET More on CSPC Pharmaceutical, Moderna, etc. Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Mitsubi...
2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...
2024-07-11 14:19:51 ET Summary Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist weight loss drug danuglipron as a once-daily oral pill. The drug met efficacy endpoints in a Phase 2 study last year as a twice daily pill, but side effects caus...
2024-07-11 12:24:00 ET Summary June CPI numbers show largest monthly decline since May 2020, bringing annual CPI down to 3%. Core CPI rose 0.1% with annual rate dropping to 3.3%, lowest since April 2021. Delta Air Lines slides after cautious guidance, while PepsiCo posts mixed...
2024-07-11 11:50:00 ET Summary Repeated bailouts have truncated equity drawdowns and vaporized the caution that investors used to carry that they can actually lose money. Between passive fund flows and the indefatigable corporate buyback machine, the proportion of equity transacti...
2024-07-11 09:24:00 ET U.S. stock index futures on Thursday pointed to a higher open, after the latest consumer price index report showed a further cooling in inflation. Here are some stocks to watch on Thursday: ... Read the full article on Seeking Alpha For further de...
2024-07-11 08:13:07 ET Pfizer Inc (NYSE: PFE) is in focus today after announcing plans of proceeding with a once-a-day formulation of danuglipron – its weight-loss drug. Encouraging data from an ongoing early-stage study informed its decision to move forward with that variant...
2024-07-11 07:18:20 ET Buoyed by encouraging pharmacokinetic data from an ongoing study, Pfizer ( NYSE: PFE ) has decided to proceed with the development of a once-daily formulation of its oral weight-loss drug, danuglipron.... Read the full article on Seeking Alpha ...
Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...